Jun 06, 2019
Hoth Therapeutics Forms Wholly Owned Australian Subsidiary, in Preparation of Upcoming Clinical Trials for Atopic Dermatitis Solution
May 07, 2019
Is Hoth Therapeutics, Inc. (NasdaqCM: HOTH) BioLexa Platform Set To Disrupt The $7 Billion Eczema And Diabetic Skin Disorder Market?
May 06, 2019
Connect Biopharma Reports Positive Phase 1 Data and Announces Initiation of Phase 1b Study in Patients with Atopic Dermatitis for Novel IL-4Ra Antibody CBP-201
Apr 09, 2019
Tremotyx Debuts Plant Stem Cell-Based Eczema Treatment in the U.S.
Mar 11, 2019
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Mar 11, 2019
Hoth Therapeutics Announces Dr. Jonathan Zippin as Senior Scientific Advisor
Mar 08, 2019
FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps
Mar 04, 2019
Hoth Therapeutics, Inc. to Begin Pilot Study at Massachusetts General Hospital Vaccine and Immunotherapy Center
Feb 27, 2019
Overall Use of Sanofi/Regeneron's Dupixent for the Treatment of Atopic Dermatitis in the EU5 Lags that of the US, Though Side Effects and Short-Term Use in Both Markets May be Cause for Concern
Feb 27, 2019
TARGET PharmaSolutions® to Advance Dermatology Research, including Atopic Dermatitis, through New Collaboration
Feb 25, 2019
AbbVie to Showcase Scientific Innovation and Research Advancements Across Dermatology Portfolio at 2019 AAD Annual Meeting
Feb 13, 2019
TARGET PharmaSolutions® Launches TARGET-DERM Real-World Observational Study to Advance the Understanding of Atopic Dermatitis (Eczema) and Other Immune-Mediated Inflammatory Skin Conditions
Jan 15, 2019
Southeast Asia Atopic Dermatitis Therapeutics Markets to 2024 - How will Novel IL-4Ra Inhibitor Therapy Dupixent, which Holds First-to-Market Advantage, Contribute to Growth
Jan 02, 2019
AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema
Nov 20, 2018
World Institute of Kimchi: Lactic acid bacteria isolated from kimchi was found to mitigate atopic dermatitis symptoms and adjust the microbiome
Nov 07, 2018
Sanofi/Regeneron's Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment
Nov 06, 2018
FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
Oct 31, 2018
Atopic Dermatitis Drugs Market Size Worth $6.41 Billion by 2022: Grand View Research, Inc.
Oct 30, 2018
Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent
Oct 18, 2018
Oral DS107 Found to Reverse the Molecular Signature of Moderate to Severe Atopic Dermatitis Patients in a Phase 2 Trial